Form 4: TriSalus Life Sciences Director Acquires Stock Options

Andrew C. von Eschenbach, a director of TriSalus Life Sciences, acquired stock options for 15,000 shares on August 13, 2024.

Summary

• Andrew C. von Eschenbach, a director at TriSalus Life Sciences, acquired stock options on August 13, 2024.
• The options grant him the right to buy 15,000 shares of common stock at an exercise price of $5.75.
• The options vest fully on August 13, 2025, or the date of the next annual stockholder meeting, contingent on continued service with the Issuer.
• The options expire on August 12, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction (stock option grant) which is generally viewed neutrally to positively as it aligns director interests with shareholders. There are no red flags or negative indicators.

Positives

• The acquisition of stock options by a director signals confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in publicly traded companies, used to incentivize and align their interests with shareholders.
• The vesting schedule of one year is fairly typical, although some companies may use different vesting periods or performance-based vesting criteria.
• The exercise price is set at $5.75, which may be at or near the current market price of the stock at the time of the grant.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates